Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Olanzapine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 937Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Teva Completes Phase 3 Trial For Olanzapine LAI In Schizophrenia
    Teva Completes Phase 3 Trial For Olanzapine LAI In Schizophrenia

    10 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250209967526/en

    BUSINESSWIRE
    10 Feb 2025
    Share Share
    Sunshine Biopharma launches Olanzapine and Olanzapine ODT
    Sunshine Biopharma launches Olanzapine and Olanzapine ODT

    22 Jan 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/sunshine-biopharma-launches-olanzapine-and-olanzapine-odt-16694

    INDPHARMAPOST
    22 Jan 2025
    Share Share
    Enforcement Report - Week of December 25, 2024
    Enforcement Report - Week of December 25, 2024

    25 Dec 2024

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-december-25-2024-24704.pdf

    FDA
    25 Dec 2024
    Share Share
    Teva Presents Schizophrenia Research, Phase 3 SOLARIS Trial Results
    Teva Presents Schizophrenia Research, Phase 3 SOLARIS Trial Results

    01 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/01/2973519/0/en/Teva-Presents-Latest-Schizophrenia-Treatment-Research-Including-Phase-3-SOLARIS-Trial-Results-Demonstrating-Improvements-in-Social-Functioning-and-Quality-of-Life-in-Adults-Receivi.html

    GLOBENEWSWIRE
    01 Nov 2024
    Share Share
    Teva Presents TEV-'749 Phase 3 Data For Schizophrenia
    Teva Presents TEV-'749 Phase 3 Data For Schizophrenia

    21 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/21/2949935/0/en/Teva-Presents-New-Phase-3-Efficacy-Safety-and-Tolerability-Data-from-SOLARIS-Trial-Evaluating-TEV-749-olanzapine-as-a-Once-Monthly-Subcutaneous-Long-Acting-Injectable-for-Adult-Pat.html

    GLOBENEWSWIRE
    21 Sep 2024
    Share Share
    Medincell’s Partner Teva Updates on Phase 3 of Olanzapine Long-Acting Injectable
    Medincell’s Partner Teva Updates on Phase 3 of Olanzapine Long-Acting Injectable

    05 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240904246149/en

    BUSINESSWIRE
    05 Sep 2024
    Share Share